Curis (NASDAQ:CRIS) Raised to “Hold” at Zacks Investment Research

Curis (NASDAQ:CRISGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Monday, Zacks.com reports.

According to Zacks, “Curis, Inc. is a therapeutic drug development company focusing on cancer, neurological and dermatological disease indications, with technologies that utilize regulatory pathways that control repair and regeneration. Curis’ product development involves the use of small molecules or proteins to modulate these pathways. The company has successfully used this technology and product development approach to produce several promising drug product candidates in the fields of cancer, neurological disorders, hair growth, kidney and other diseases, as well as cardiovascular disease. “

Other equities analysts have also recently issued reports about the company. Cantor Fitzgerald cut their price target on Curis from $12.00 to $4.00 in a report on Tuesday, April 5th. StockNews.com started coverage on Curis in a report on Thursday, March 31st. They issued a “sell” rating for the company. B. Riley cut their price target on Curis from $22.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, April 5th. Finally, Raymond James lowered Curis from an “outperform” rating to a “market perform” rating and set a $15.00 target price for the company. in a research note on Monday, April 4th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $10.85.

Shares of CRIS stock traded up $0.04 during midday trading on Monday, hitting $1.03. The company had a trading volume of 1,390,624 shares, compared to its average volume of 2,407,933. The company’s 50 day simple moving average is $2.12 and its 200 day simple moving average is $3.80. Curis has a 52-week low of $0.91 and a 52-week high of $17.40. The stock has a market cap of $94.39 million, a price-to-earnings ratio of -2.06 and a beta of 3.15.

Curis (NASDAQ:CRISGet Rating) last posted its earnings results on Thursday, February 24th. The biotechnology company reported ($0.15) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.13) by ($0.02). The firm had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $3.04 million. Curis had a negative return on equity of 42.46% and a negative net margin of 426.67%. During the same quarter in the previous year, the firm posted ($0.11) earnings per share. Analysts forecast that Curis will post -0.63 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently made changes to their positions in CRIS. Moors & Cabot Inc. acquired a new stake in shares of Curis during the 3rd quarter worth approximately $268,000. Advisor Group Holdings Inc. increased its position in Curis by 36.1% in the 3rd quarter. Advisor Group Holdings Inc. now owns 7,540 shares of the biotechnology company’s stock valued at $58,000 after acquiring an additional 2,000 shares during the period. Royal Bank of Canada increased its position in Curis by 198.5% in the 2nd quarter. Royal Bank of Canada now owns 8,357 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 5,557 shares during the period. Cutler Group LP increased its position in Curis by 46.3% in the 4th quarter. Cutler Group LP now owns 9,800 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 3,100 shares during the period. Finally, Virtu Financial LLC bought a new position in Curis during the 4th quarter valued at $49,000. Hedge funds and other institutional investors own 78.15% of the company’s stock.

Curis Company Profile (Get Rating)

Curis, Inc, a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

Further Reading

Get a free copy of the Zacks research report on Curis (CRIS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.